Indian (NIFTY) Clinical Research and Equipment Industry Analysis
UpdatedSep 27, 2023
DataAggregated Company Financials
Companies13
- 7D-1.3%
- 3M4.0%
- 1Y8.7%
- YTD15.3%
Over the last 7 days, the Clinical Research and Equipment industry has dropped 1.3%, driven by a pullback from Syngene International of 4.0%. On the other hand Tarsons Products is actually up 5.7%. In the past year, the industry has gained 8.7%. Looking forward, earnings are forecast to grow by 22% annually.
Industry Valuation and Performance
Has the Indian Clinical Research and Equipment Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 27 Sep 2023 | ₹1.4t | ₹154.7b | ₹19.7b | 25.4x | 71x | 9x |
| Fri, 25 Aug 2023 | ₹1.4t | ₹154.7b | ₹19.7b | 27.6x | 70.2x | 8.9x |
| Sun, 23 Jul 2023 | ₹1.4t | ₹156.5b | ₹23.0b | 30x | 59.9x | 8.8x |
| Tue, 20 Jun 2023 | ₹1.3t | ₹157.2b | ₹23.0b | 28.1x | 57.8x | 8.5x |
| Thu, 18 May 2023 | ₹1.2t | ₹163.0b | ₹28.6b | 33.3x | 42.7x | 7.5x |
| Sat, 15 Apr 2023 | ₹1.2t | ₹159.5b | ₹28.4b | 34.7x | 41.3x | 7.3x |
| Mon, 13 Mar 2023 | ₹1.1t | ₹159.5b | ₹28.4b | 30.9x | 37.1x | 6.6x |
| Wed, 08 Feb 2023 | ₹1.0t | ₹158.6b | ₹28.4b | 30.5x | 36.2x | 6.5x |
| Fri, 06 Jan 2023 | ₹1.2t | ₹164.9b | ₹34.5b | 30.7x | 35.9x | 7.5x |
| Sun, 04 Dec 2022 | ₹1.2t | ₹164.9b | ₹34.5b | 30x | 35.6x | 7.4x |
| Tue, 01 Nov 2022 | ₹1.3t | ₹164.1b | ₹36.1b | 37x | 35.9x | 7.9x |
| Thu, 29 Sep 2022 | ₹1.3t | ₹162.5b | ₹35.7b | 36.6x | 36x | 7.9x |
| Sat, 27 Aug 2022 | ₹1.3t | ₹162.6b | ₹35.8b | 37.2x | 35.8x | 7.9x |
| Mon, 25 Jul 2022 | ₹1.3t | ₹158.8b | ₹34.2b | 34x | 38.9x | 8.4x |
| Wed, 22 Jun 2022 | ₹1.3t | ₹158.3b | ₹34.2b | 32.3x | 36.8x | 7.9x |
| Fri, 20 May 2022 | ₹1.4t | ₹149.8b | ₹30.2b | 34.5x | 46.8x | 9.4x |
| Sun, 17 Apr 2022 | ₹1.6t | ₹148.3b | ₹29.4b | 38.2x | 52.8x | 10.5x |
| Tue, 15 Mar 2022 | ₹1.5t | ₹148.3b | ₹29.4b | 34.6x | 51x | 10.1x |
| Thu, 10 Feb 2022 | ₹1.5t | ₹139.8b | ₹25.1b | 36.1x | 59.5x | 10.7x |
| Sat, 08 Jan 2022 | ₹1.6t | ₹137.8b | ₹24.6b | 32.6x | 63.6x | 11.3x |
| Mon, 06 Dec 2021 | ₹1.6t | ₹137.8b | ₹24.6b | 31.6x | 65.7x | 11.7x |
| Wed, 03 Nov 2021 | ₹1.7t | ₹132.3b | ₹22.7b | n/a | 74.3x | 12.7x |
| Fri, 01 Oct 2021 | ₹1.6t | ₹131.1b | ₹22.9b | 22.9x | 69.3x | 12.1x |
| Sun, 29 Aug 2021 | ₹1.6t | ₹131.4b | ₹22.9b | 22.1x | 70.7x | 12.3x |
| Mon, 05 Jul 2021 | ₹1.5t | ₹127.1b | ₹22.6b | 36.9x | 65.2x | 11.6x |
| Thu, 08 Apr 2021 | ₹1.2t | ₹121.4b | ₹21.5b | 32.5x | 56.9x | 10.1x |
| Sun, 10 Jan 2021 | ₹1.3t | ₹116.0b | ₹22.4b | 40x | 58.6x | 11.3x |
| Sat, 03 Oct 2020 | ₹1.1t | ₹114.7b | ₹22.2b | 27.1x | 48.1x | 9.3x |
Price to Earnings Ratio
48.1x
Current Industry PE
- Investors are optimistic on the Indian Life Sciences Tools and Services industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 71.0x which is higher than its 3-year average PE of 52.4x.
- The industry is trading close to its 3-year average PS ratio of 9.6x.
Past Earnings Growth
- The earnings for companies in the Life Sciences Tools and Services industry have declined 3.9% per year over the last three years.
- Meanwhile revenues for these companies have grown 10% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Comparison
How does Indian Clinical Research and Equipment compare with similar industries?
| IN Market | -1.54% | |
| Healthcare | -2.49% | |
| Life Sciences | -1.29% | |
| Clinical Research and Equipment | -1.29% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| TARSONS Tarsons Products | ₹561.35 | 6.6% +₹2.1b | -29.9% | PE43.1x | |
| DCAL Dishman Carbogen Amcis | ₹165.15 | 6.5% +₹1.6b | 76.4% | PS1x | |
| 524394 Vimta Labs | ₹553.35 | 3.3% +₹395.4m | 71.1% | PE25.4x | |
| 511509 Vivo Bio Tech | ₹35.64 | 1.5% +₹7.7m | -0.3% | PE21.5x |